Moleculin Biotech (DB:MOL) - Prezzo delle azioni, notizie e analisi

MOL Panoramica delle azioni

A clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Maggiori dettagli

MOL analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	4/6
Dividendi	0/6

Analisi del rischio

Le azioni sono altamente illiquide

Ha meno di 1 anno di pista di cassa

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Non ha una capitalizzazione di mercato significativa ( €9M )

+ 2 più rischi

Moleculin Biotech, Inc. Concorrenti

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€17.4m

4SC

DB:VSC

€50.2m

bioXXmed

XTRA:T5O

€1.4m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Moleculin Biotech
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$6.45
Massimo di 52 settimane	US$12.75
Minimo di 52 settimane	US$3.99
Beta	1.86
1Variazione di 1 mese	0%
Variazione a 3 mesi	-6.93%
Variazione di 1 anno	-15.69%
3Variazione a 3 anni	-85.52%
Variazione a 5 anni	-93.11%
Variazione dall'IPO	-98.77%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	MOL	DE Biotechs	DE Mercato
7D	0%	0.8%	0.8%
1Y	-15.7%	-18.3%	8.6%

Ritorno vs Industria: MOL ha superato il German Biotechs che ha restituito -18.3 % nell'ultimo anno.

Rendimento vs Mercato: MOL ha avuto una performance inferiore al mercato German che ha registrato un rendimento 8.6 % nell'ultimo anno.

Volatilità dei prezzi

Is MOL's price volatile compared to industry and market?
MOL volatility
MOL Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: Il prezzo delle azioni di MOL è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di MOL nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2015	18	Wally Klemp	moleculin.com

Moleculin Biotech, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Moleculin Biotech con la sua capitalizzazione di mercato?
MOL statistiche fondamentali
Capitalizzazione di mercato	€8.48m
Guadagni(TTM)	-€24.98m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-0.3x

Rapporto P/E

MOL è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
MOL Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$0
Profitto lordo	US$0
Altre spese	US$26.82m
Guadagni	-US$26.82m

Ultimi guadagni dichiarati

Mar 31, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-11.60
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	0%

Come si è comportato MOL nel lungo periodo?

Vedi performance storica e confronto

MOL Panoramica delle azioni

Analisi del rischio

Moleculin Biotech, Inc. Concorrenti

XTRA:CNW

€6.5m

XTRA:MDG1

€17.4m

DB:VSC

€50.2m

XTRA:T5O

€1.4m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Moleculin Biotech, Inc. Announces New Findings Supporting the Ability of Annamycin Overcomes Resistance to Venetoclax in AML

Moleculin Biotech, Inc. Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)

Moleculin Biotech, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Moleculin Biotech, Inc., Annual General Meeting, Oct 24, 2024

Moleculin Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $5.497817 million.

Recent updates

Moleculin Biotech, Inc. Announces New Findings Supporting the Ability of Annamycin Overcomes Resistance to Venetoclax in AML

Moleculin Biotech, Inc. Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)

Moleculin Biotech, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Moleculin Biotech, Inc., Annual General Meeting, Oct 24, 2024

Moleculin Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $5.497817 million.

Moleculin Biotech, Inc. Announces Plans for MIRACLE Phase 3 Pivotal Trial

Moleculin Biotech, Inc. has filed a Follow-on Equity Offering.

Moleculin Biotech, Inc. Completes End of Phase 2 Meeting with FDA for Annamycin in AML

Moleculin Biotech, Inc. Announces Additional Positive Preliminary Interim Data from AML Clinical Trial

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (Nu 21C06)

Moleculin Biotech, Inc. to Report Q1, 2024 Results on May 10, 2024

Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data

Moleculin Biotech, Inc. Announces Formation of Annamycin Scientific Advisory Board and Inaugural Appointment of Martin Tallman

Moleculin Biotech, Inc Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial

New major risk - Financial position

Moleculin Biotech, Inc. to Report Fiscal Year 2023 Results on Mar 22, 2024

Moleculin Biotech, Inc. Announces Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Moleculin Biotech, Inc. Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3

Moleculin Biotech, Inc. announced that it expects to receive $9.01739 million in funding

New major risk - Financial position

Moleculin Biotech, Inc. Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months

Moleculin Biotech, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Moleculin Biotech Receives an Extension of the 180 Calendar Days from Nasdaq to Regain Compliance with the Bid Price Requirement

Moleculin Biotech, Inc. Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

Moleculin Biotech, Inc. Announces New Positive Independent Report of No Cardiotoxicity in Annamycin

New major risk - Financial position

Moleculin Biotech, Inc. Provides Update on Ongoing Clinical Trials

Moleculin Biotech, Inc. to Report Q2, 2023 Results on Aug 11, 2023

Moleculin Biotech, Inc., Annual General Meeting, Jun 15, 2023

Moleculin Biotech Receives Non-Compliance Notice From Nasdaq

Moleculin Biotech, Inc. to Report Q1, 2023 Results on May 11, 2023

Moleculin Biotech, Inc. Announces Final Topline Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Moleculin Biotech, Inc. Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia

Moleculin Biotech, Inc. Receives FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme

Founder recently bought €55k worth of stock

Founder recently bought €104k worth of stock

Moleculin Biotech, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Moleculin Biotech, Inc Provides Update on Second Multiple Ascending Dose (MAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

Moleculin Biotech, Inc. Announces WP1096 Molecule Will Be Evaluated in Animal Studies Through the Preclinical Services Offered by the National Institute of Allergy and Infectious Diseases

Moleculin Biotech, Inc. Announces Completion of Third Single Ascending Dose Cohort in Phase 1A Clinical Trial of Wp1122 in the UK

Moleculin Concludes Phase 1B and Opens Recruitment in Phase 2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

Moleculin Biotech, Inc. Announces Completion of Second Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

Moleculin Biotech, Inc. Announces Completion of First Single Ascending Dose (Sad) Cohort in Phase 1A Clinical Trial of Wp1122 in the UK

Moleculin Biotech, Inc. Announces the Commencement of Dosing in Its First-In-Human Phase 1A Study to Evaluate the Safety and Pharmacokinetics (PK) of Wp1122 in Healthy Volunteers for the Treatment of COVID-19 (MB-301)

Moleculin Biotech, Inc. Announces the Commencement of Dosing in Its First-In-Human Phase 1A Study to Evaluate the Safety and Pharmacokinetics (PK) of Wp1122 in Healthy Volunteers for the Treatment of COVID-19 (MB-301)

Moleculin Biotech, Inc Receives Approval from the UK's Medicines and Healthcare Products Regulatory Agency for Protocol Amendment to Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19

Moleculin Biotech, Inc. Receives Allowance to Proceed with Phase 1/2 Study of Annamycin

Moleculin Biotech, Inc. Engages Wolfram C. M. Dempke, MD, PhD, MBA as its European Chief Medical Officer

Moleculin Biotech, Inc. Receives IND Clearance to Conduct Phase 1 Study of WP1066 for Treatment of Recurrent Malignant Glioma

Moleculin Biotech, Inc., Annual General Meeting, May 26, 2022

Moleculin Biotech, Inc. Announces Presentation of Positive Preclinical Annamycin Data At the AACR 2022 Annual Meeting

Moleculin Biotech, Inc. Announces Appointment of Joy Yan, M.D., Ph.D. to Board of Directors

Moleculin Announces Updated Preliminary Safety Data for Annamycin in Its Three Phase 1 Clinical Trials for Acute Myeloid Leukemia and Metastases of Soft Tissue Sarcoma

Moleculin Biotech, Inc. Announces Preliminary Third Cohort Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

Moleculin Biotech, Inc. Receives FDA Allowance to Begin a Phase 1 Study of WP1122 for the Treatment of Glioblastoma Multiforme

High number of new and inexperienced directors

High number of new and inexperienced directors

Moleculin Receives Approval to Extend Dose Escalation in Phase 1/2 European Clinical Trial Evaluating Annamycin for the Treatment of Acute Myeloid Leukemia

Moleculin Biotech, Inc. Announces First Subject Enrolled and Dosed in Phase 1B/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases